William Blair Downgrades Revance Therapeutics to Market Perform
Portfolio Pulse from Benzinga Newsdesk
William Blair analyst Tim Lugo has downgraded Revance Therapeutics (NASDAQ:RVNC) from Outperform to Market Perform.
August 12, 2024 | 5:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
William Blair analyst Tim Lugo has downgraded Revance Therapeutics from Outperform to Market Perform, which may negatively impact the stock price in the short term.
Analyst downgrades typically lead to a negative short-term impact on the stock price as they reflect a less favorable outlook on the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100